|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Clinical Care/Education/Nutrition |
Comparison of the Effects of Three Insulinotropic Drugs on Plasma Insulin Levels After a Standard Meal
1 Diabetes Research Unit, University Hospital of Wales, College of Medicine, South Glamorgan, Wales
2 Novo Nordisk A/S, Bagsvaerd, Denmark
3 Med Universitatsklinik Graz, Graz, Austria
OBJECTIVE—To compare the effects of repaglinide, glipizide, and glibenclamide on insulin secretion and postprandial glucose after a single standard 500-kcal test meal.
RESEARCH DESIGN AND METHODS—A total of 12 type 2 diabetic patients with early diabetes (mean HbA1c of 6.1%) and 12 matched control subjects were enrolled in this randomized, double-blind, crossover trial. Subjects received placebo, 2 mg repaglinide, 5 mg glipizide, and 5 mg glibenclamide in a random fashion during the trial. Administration of each drug was followed by a single standard 500-kcal test meal. A washout period of 7–12 days existed between the four study visits.
RESULTS—All three drugs were equally effective on the total prandial insulin secretion (area under the curve [AUC] -15 to 240 min). However, clear differences were noted in the early insulin secretion (AUC -15 to 30 min); both repaglinide and glipizide increased secretion in nondiabetic subjects by 
61 and 34%, respectively, compared with placebo. In the diabetic patients, the difference versus placebo was 37 and 47%, respectively. The difference between glipizide and glibenclamide reached significance in both groups of subjects, whereas repaglinide was more effective than glibenclamide only in the healthy nondiabetic subject group. All three drugs were effective in decreasing total glucose AUC in the nondiabetic and diabetic population. In the nondiabetic subjects, however, repaglinide was significantly more effective than glibenclamide. The differences disappeared in the diabetic subjects, probably as a result of increased prevalence of insulin resistance in this group.
CONCLUSIONS—Repaglinide and glipizide but not glibenclamide significantly enhanced the early insulin secretion in both nondiabetic and diabetic subjects with preserved ß-cell function after a single standard meal.
Abbreviations: AUC, area under the curve • CVD, cardiovascular disease • KATP, ATP-sensitive potassium
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  L. S. Cozma, S. D. Luzio, G. J. Dunseath, P. M. Underwood, and D. R. Owens {beta}-Cell Response During a Meal Test: A comparative study of incremental doses of repaglinide in type 2 diabetic patients Diabetes Care, May 1, 2005; 28(5): 1001 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Aldhahi, J. Armstrong, C. Bouche, R. D. Carr, A. Moses, and A. B. Goldfine {beta}-Cell Insulin Secretory Response to Oral Hypoglycemic Agents Is Blunted in Humans in Vivo during Moderate Hypoglycemia J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4553 - 4557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Esposito, D. Giugliano, F. Nappo, R. Marfella, and for the Campanian Postprandial Hyperglycemia Study Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus Circulation, July 13, 2004; 110(2): 214 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Sheehan Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach Clin. Med. Res., July 1, 2003; 1(3): 189 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Cohen and B. A. Ramlo-Halsted How Do the New Insulin Secretagogues Compare? Diabetes Care, August 1, 2002; 25(8): 1472 - 1473. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |